Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment Regimens for Mifegyne and Cytotec

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by Western Galilee Hospital-Nahariya.
Recruitment status was  Recruiting
Information provided by:
Western Galilee Hospital-Nahariya Identifier:
First received: June 12, 2009
Last updated: May 24, 2011
Last verified: November 2010

The purpose of this study is to test two regimens of mifegyne and cytotec for medical abortion. The investigators hypothesize that administration of both medications during one hospital visit will not compromise effectiveness.

Condition Intervention Phase
Medical Abortion
Drug: mifegyne and cytotec
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Comparison of the Effectiveness of Abortive Measures From the Administration of Mifegyne and Cytotec at One and Two Visits

Resource links provided by NLM:

Further study details as provided by Western Galilee Hospital-Nahariya:

Primary Outcome Measures:
  • percentage of complete abortion [ Time Frame: one month ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: June 2009
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: one-visit Drug: mifegyne and cytotec
One day dosage versus two days dosage
Other Name: Comparison of one day dosing to two days dosing
Active Comparator: two-visit Drug: mifegyne and cytotec
One day dosage versus two days dosage
Other Name: Comparison of one day dosing to two days dosing


Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • above age 18,
  • for whom Mifegyne and cytotec are indicated.

Exclusion Criteria:

  • inflammation of oral cavity.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00920465

Western Galilee Hospital- Nahariya Recruiting
Nahariya, Israel, 22100
Contact: Renee Tendler, MD   
Sponsors and Collaborators
Western Galilee Hospital-Nahariya
  More Information

No publications provided

Responsible Party: Dr. Renee Tendler, Western Galilee Hospital-Nahariya Identifier: NCT00920465     History of Changes
Other Study ID Numbers: 4-10-2007
Study First Received: June 12, 2009
Last Updated: May 24, 2011
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Abortifacient Agents, Steroidal
Anti-Ulcer Agents
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Contraceptives, Postcoital
Contraceptives, Postcoital, Synthetic
Gastrointestinal Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses processed this record on November 20, 2014